JP MORGAN CONFERENCE January 2020 Exhibit 99.3

disclaimer Matters discussed in this presentation may constitute forward-looking statements. The forward-looking statements contained in this presentation reflect our views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and changes in circumstances that may cause our actual results, performance, or achievements to differ significantly from those expressed or implied in any forward-looking statement. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future events, results, performance, or achievements. Some of the key factors that could cause actual results to differ from our expectations include our plans to develop and potentially commercialize our product candidates; our planned clinical trials and preclinical studies for our product candidates; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the extent of clinical trials potentially required for our product candidates; the clinical utility and market acceptance of our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position; and our ability to identify and in-license additional product candidates. For further information regarding these risks, uncertainties and other factors that could cause our actual results to differ from our expectations, you should read our Annual Report on Form 20-F for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on March 5, 2019 and our other filings we make with the Securities and Exchange Commission from time to time. We expressly disclaim any obligation to update or revise the information herein, including the forward-looking statements, except as required by law. Please also note that this presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities. This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Focused on unmet needs in women’s health LINZAGOLIX OBE022 Potential to delay preterm birth to improve newborn health and reduce medical costs Potential to relieve symptoms from heavy menstrual bleeding due to uterine fibroids and pain associated with endometriosis NOLASIBAN Potential to improve live birth rate following IVF & ET (repositioning)

Multiple Late-Stage programs to drive value * Primary and secondary endpoints met PHASE 1 PHASE 2 PHASE 3 MARKET SIZE MILESTONES LINZAGOLIX (OBE2109) Oral GnRH receptor antagonist ~4M women diagnosed and treated in U.S. Positive 24W primary endpoint results 24W primary endpoint data Q2:20 MAA/NDA: Q4:20 / Q1:21 ~5M women diagnosed and treated in U.S. Initiated Ph3 in Q2:19 Positive Phase 2b results in 2018/19 OBE022 Oral PGF2α receptor antagonist 500,000 annual cases in each of U.S and Europe Interim update in 60 patients Q1:20 Pre-clinical/Phase 1 complete NOLASIBAN Oral oxytocin receptor antagonist Resuming development > 2M IVF Global cycles/year Positive IMPLANT 2 Ph3 Results IMPLANT 4 Ph3 missed primary endpoint Partnership with Hangzhou Yuyuan BioScience (PRC) Uterine Fibroids – Ph3 PRIMROSE 1 U.S. Preterm Labor – Ph2a PROLONG * IVF – Ph3 IMPLANT 2/4 EU Uterine Fibroids – Ph3 PRIMROSE 2 EU & U.S. * Endometriosis – Ph3 EDELWEISS 2 U.S. Endometriosis – Ph3 EDELWEISS 3 EU & U.S. Endometriosis – Ph2b EDELWEISS Preterm Labor – Ph1 IVF – Ph 1/2 in China

2020 catalysts Multiple value driving catalysts in the upcoming year Two ongoing Phase 3 linzagolix trials in uterine fibroids to generate additional data starting in Q2:20 First linzagolix regulatory filing in uterine fibroids planned for late 2020 Phase 2 results of OBE022 expected in 2H:20 Corporate objective to establish commercial partnerships for Linzagolix that maximize compound value and prudently manage cash investments Resuming Nolasiban in IVF – YUYUAN Ltd (CHINA) partnership – aiming at assessing higher and longer exposure to nolasiban around embryo transfer in a potentially “enriched” IVF population

Linzagolix (OBE2109) Optimizing Approach for Reducing Estrogen To Treat Uterine Fibroids and Endometriosis

Linzagolix: Dose-dependent Reduction of Estrogen to Treat Uterine Fibroids & Endometriosis Linzagolix binds competitively to pituitary gland GnRH receptors Prevents receptor activation by endogenous GnRH Induces neither downregulation nor desensitization of the receptors Immediate onset of action leads to rapid, dose-dependent suppression of gonadotropins, LH and FSH Gonadotropin suppression leads to a dose-dependent decrease in blood estradiol concentration Validated MoA: Inhibition of endogenous GnRH signaling GnRH antagonist Ovary GnRH Hypothalamus Anterior pituitary gland FSH, LH Uterus Estradiol

Linzagolix: Pk profile Note: The data on this page are not from head-to-head comparisons. * In a dedicated food effect study using a single 200 mg dose, there was a decrease of 24% and 36% in AUC and Cmax, respectively, under high-fat meal conditions; however, labelling states elagolix can be taken without regard to meals. Linzagolix Orilissa (Elagolix) Relugolix Dose options Endometriosis 75 mg 200 mg with ABT 150 mg 400 mg (200 BID) with ABT 40 mg with ABT Uterine Fibroids 100 mg 200 mg with ABT 600 mg (300 BID) with ABT 40 mg with ABT Dosing frequency / day 1 x 1x or 2x 1x PK Characteristics Half-Life 14-15 hours 2-6 hours 37-42 hours Bioavailability > 80% 30 – 50% 11% Hepatic Elimination Moderate Major Major Food Effect No No* Yes CYP3A4 induction (ABT, contraception) No Yes No

Uterine fibroids: A Large Market With Unmet Need Total U.S. costs estimated at up to from direct costs, lost workdays and complications $34B /yr 9 million women in the U.S. suffer from fibroids 70%+ of women have fibroids by age 50 Quality of Life Premenopausal women may experience heavy menstrual bleeding, anemia, bloating, infertility, pain and swelling 600,000 Hysterectomies are performed annually in the U.S. 300,000 Are because of uterine fibroids > 4 million women in the U.S. are treated annually for fibroids

MethodDiscreet choice modeling based on the responses of 101 U.S. patients with symptomatic uterine fibroids Market feedback what matters for uterine fibroids patients? Source: AplusA US patient research (n = 101), Oct-Dec 2019 The ‘full package’ is required to win 1 ABT matters for women 2 Rank ordered perceived incremental value of the tested component levels in UF patients choice Utility values are calculated for each attribute level to express their perceived relative value for patients when choosing the UF treatment they would prefer to receive instead of the current/latest one

Primrose 1 & 2: Phase 3 clinical trials for the Treatment of Uterine Fibroids The trial was powered under the assumption of a 30% placebo response rate based on historical studies PRIMROSE 1 100% U.S. sites PRIMROSE 2 70% European sites 30% U.S. sites Main Study (N=500, 100/arm) Follow up 24 Weeks Primary Endpoint: Responder-HMB Reduction Q4:19/Q2:20 Placebo + placebo add-back 100 mg + placebo add-back 100 mg + add-back 200 mg + placebo add-back 200 mg + add-back Placebo + placebo add-back 100 mg + placebo add-back 100 mg + add-back 200 mg + placebo add-back 200 mg + add-back 28 Weeks 24 Weeks Screening Screening Follow-up 100 mg + add-back 200 mg + add-back 100mg + placebo add-back 200 mg + add-back 200 mg + add-back Follow-up 100 mg + add-back 200 mg + add-back 100 mg + placebo add-back 200mg + add-back 200 mg + add-back Placebo + placebo add-back 8-14 Weeks Aiming to support the registration of two regimens of administration

PRIMROSE 2: Demographic and Baseline Characteristics * Anemia = hemoglobin value is less than less than 12.0 g/dL ** MBL: Menstrual Blood Loss Full Analysis Set Placebo n=102 Linzagolix 100 mg n=97 Linzagolix 100 mg + ABT n=101 Linzagolix 200 mg n=103 Linzagolix 200 mg + ABT n=98 Total n=501 Age (years) - mean (SD) 42.9 (5.3) 43.4 (5.4) 42.5 (5.1) 42.7 (5.8) 43.1 (4.8) 42.9 (5.3) BMI (kg/m2 ) - mean (SD) 26.83 (5.42) 27.44 (5.67) 27.22 (5.82) 26.82 (5.55) 26.80 (5.47) 27.02 (5.57) Hb < 10 g/dL – n(%) 14 (13.7) 21 (21.6) 16 (15.8) 18 (17.5) 24 (24.5) 93 (18.6) Hb < 12 g/dL – n(%)* 51 (50.0) 61 (62.9) 59 (58.4) 57 (55.3) 56 (57.1) 284 (56.7) MBL** (mL) at baseline mean (SD) 218 (128) 246 (161) 193 (92) 219 (136) 212 (142) 218 (134) 95% Caucasian / 5% Black

Primrose 2 Phase 3 – Uterine Fibroids Dose-dependent suppression of E2 ABT = Add Back Therapy (ActivellaTM ) E2 Target Range E2 range: symptom relief without BMD harm

Primrose 2 – Primary endpoint achieved for BOTH target DOSing REGIMEns – Responder* analysis Error bars are 95% CI PROPORTION OF WOMEN 100 80 60 40 20 0 29.4% 56.7% 93.9% Placebo Linzagolix 100mg Linzagolix 200mg + ABT P<0.001 P<0.001 *Proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline

KEY SECONDARY ENDPOINTS ACHIEVED Key Secondary Endpoints Measurement p-value Reduction in menstrual blood loss Time to reduced menstrual blood loss (i.e., ≤80 mL and ≥50% reduction from baseline) up to Week 24 Number of days of uterine bleeding for the last 28-day interval prior to Week 24 p < 0.001 p < 0.001 Amenorrhea Percentage at Week 24 Time to amenorrhea up to Week 24 p < 0.001 p < 0.001 Improvement in anemia Hemoglobin level at week 24 in anemic subjects (defined as subjects with Hb < 12 g/dL at baseline) p < 0.001 Reduction in pain Change from baseline pain score at week 24 p < 0.001 Reduction in volume Fibroid volume change from baseline at Week 24 for 100mg without ABT and 200mg with ABT Uterine volume change from baseline at Week 24 p < 0.055/0.008 p < 0.001 Improvement in quality of life Change from baseline health-related quality of life (UFS-QoL*) at Week 24 p < 0.001 * UFS-QoL = Uterine Fibroids Symptoms and Health-Related Quality of Life questionnaire

PRIMROSE 2: SIGNIFICANT Amenorrhea response for both target DOSES Note: Error bars are 95% CI PROPORTION OF WOMEN WITH AMENORRHEA 100 80 60 40 20 0 11.8% 34.0% 80.6% Placebo Linzagolix 100mg Linzagolix 200mg + ABT p<0.001 p<0.001

Primrose 2: PAIN REDUCTION and patient satisfaction for BOTH target DOSES Note: Error bars are 95% CI; * p<0.001 Baseline Week 12 Week 24 * * * * Patient Global Impression of Improvement 33.3 48.7 73.5 75.0 87.5 p=0.047 p<0.001 p<0.001 p<0.001 Pain Reduction

Recent trials of GnRH antagonists in uterine fibroids Source: Company information – Note: NR = not reported. ² PRIMARY ENDPOINT: Proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline Linzagolix Relugolix Elagolix PRIMROSE 2 LIBERTY 1 LIBERTY 2 ELARIS 1 ELARIS 2 Mean Age (y) 43.1 41.3 42.1 42.6 42.5 Baseline Menstrual Blood Loss (mL per cycle) 212 229 227 238 229 Dose Regimen 200mg + ABT Once daily 40mg + ABT Once daily 300mg + ABT Twice daily Responder² Rate (RR) (%) 93.9 73.4 71.3 68.5 76.5 Placebo-adjusted RR (%) 64.5 54.8 56.5 60.0 66.0 Amenorrhea (%) 80.6 52.3 50.4 48.1 52.9 Placebo-adjusted RR (%) 68.8 46.8 - 43.7 48.2 Pain Fibroid Volume Uterine Volume Menstrual Blood Loss Anemia Quality of Life ü ü ü ü ü ü ü û ü ü ü ü ü û ü ü ü ü NR NR NR ü ü ü NR NR NR ü ü ü BMD Loss (%, Spine) -1.31 -0.36 -0.13 -0.76 -0.61 Caution advised when comparing across clinical trials. Below data are not head-to-head comparison, and no head-to-head trials have been completed, nor are underway

SUMMARY OF ADVERSE EVENTS Treatment emergent adverse events, n (%) Placebo n=105 Linzagolix 100 mg n=99 Linzagolix 100 mg + ABT n=102 Linzagolix 200 mg n=104 Linzagolix 200 mg + ABT n=101 Total n=511 Subjects with at least one TEAE 47 (44.8) 50 (50.5) 45 (44.1) 62 (59.6) 51 (50.5) 255 (49.9) Vascular disorders* 6 (5.7) 15 (15.2) 12 (11.8) 36 (34.6) 14 (13.9) 83 (16.2) * Vascular disorders include hot flushes, hypertension, flushing, varicose veins Most common TEAEs (>5%) Hot flushes (13.9%) Anemia (10.4%) Headache (6.8%)

PRIMROSE 2 BMD % change FROM BASELINE at week 24 Consistent With Indicative references Patients in the trial received no vitamin D or calcium supplementation ELAGOLIX/MPA “The absence of significant bone loss was supported if the lower bounds of the CIs for the mean percentage change in BMD were ≥−2.2% for both the spine and femur at week 24, which was selected to reflect recommendations from the FDA (internal communication)”* * Carr B, Dmowski PD, O’Brien C, Jiang P, Burke J, Jimenez R, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: Effects on bone mineral density. Reproductive Sciences 2014; 21(11): 1341-51. ELAGOLIX NDA Review 2018 “FDA considers BMD loss of ≤ 3% to be within the variability of DXA measurement.”

Race is one of the most important determinants of BMD Blacks consistently reported to have higher BMD than other races1,2 Unadjusted LS/FN BMDs 7-12% & 14-24% higher in black vs white women6 Caucasian race is a known risk factor for lower BMD and fracture3,4,5 Body weight and body mass index (BMI) are positively correlated with BMD and protective against bone loss Low body weight or BMI is a risk factor for low bone mass and increased bone loss In some studies, weight more predictive than BMI PRIMROSE 2: BMD DATA INTERPRETATION (I) 1Qiao D et al, Public Health 2019;180:22-28; 2Cao J, Journal of Orthopaedic Surgery and Research 2011; 6(30); 3Albala C et al, Int J Obes Relat Metab Disord 1996; 20:1027–32; 4Asomaning K et al, J Women's Health 2006;15:1028–34; 5Nielson CM et al, J Bone Miner Res 2012; 27:1-10; 6Kim SJ et al; J Bone Metab 2012; 19(2):95-102 Literature supports relationship between BMD, RACE & BMI

PRIMROSE 2: BMD DATA INTERPRETATION (II) Study populations not similar for risk of BMD loss PRIMROSE 2 – OVERALL POPULATION PRIMROSE 2 US Only PRIMROSE 1 US only ELARIS-I (ELGX) ELARIS-2 (ELGX) LIBERTY 1 (RLGX) LIBERTY 2 (RLGX) Subjects (n) 501 48 526 308 283 255 254 Black (%) 5.2% 52% 64.3% 68/66% 67/66% 42/41% 42/42% Age (mean year/SD) 42.9 (5.3) 41.8 (5.6) 41.6 (5.9) 41/42 42/42 42/41 42/42 Height (mean cm/SD) 165.5 (6.1) 165.7 (6.8) - - - - - Weight (mean Kg/SD) 74.06 (15.90) 91.48 (19.78) - - - - - BMI (mean /SD) 27.02 (5.57) 33.29 (6.95) 32.70 (6.84) 34/33 34/33 32/31 32/31 PRIMROSE 1 trial – read-out 24 weeks – 2Q:20 In the overall population in the PRIMROSE 2 trial, the non-ABT group, BMD loss inversely related to BMI

Endometriosis: An emotionally and physically Painful condition Total U.S. costs estimated at up to $22B /yr 5 million women in the U.S. are treated annually for endometriosis Quality of Life Premenopausal women may experience pelvic pain, pain during intercourse and defecation, infertility and emotional distress 10% Endometriosis affects up to in the general population 50% in the infertile population 60% in patients with chronic pelvic pain 176 million women worldwide suffer from endometriosis 60% of women will feel symptoms by age 16

(whiskers represent 10% / 90% percentile) EDELWEISS Phase 2b – endometriosis: dose-dependEnt suppression of e2 Endometriosis Patients Week 24 Modeled E2 Data Linzagolix Daily Dose (mg) for 24 Weeks Linzagolix 75mg Linzagolix 200mg E2 concentration (pg/ml) (whiskers represent 10% / 90% percentile) Target Range E2 range: Symptom relief without BMD harm

Phase 2b EDELWEISS clinical trial: endometriosis patients **BMD: Bone Mineral Density * Titration after 12 weeks based on E2 serum level at weeks 4 and 8 MAIN STUDY FOLLOW UP Enrollment 328 patients, ~65/arm 50 sites in U.S. (n=177) 14 sites in EU (n= 151) PRIMARY ENDPOINT: VRS PAIN SCORE RESPONDER RATE JUNE 2018 SECONDARY ENDPOINT: BMD** SEPTEMBER 2018 RESULTS: 1H 2019 8–14 WEEKS LEAD-IN 50mg daily 100mg daily 200mg daily 75mg daily 75mg daily* PLACEBO 12 WEEKS 12 WEEKS 24 WEEKS 50mg daily 200mg daily 75mg daily *Titrated dose 50-100mg 100mg daily OPTIONAL EXTENSION: 6M + 6M FOLLOW-UP FOLLOW-UP

Linzagolix Phase 2b endometriosis: key doses met efficacy endpoints Potential point of differentiation as 75mg partial suppression dose is nearly as effective as 200mg full suppression dose Overall Pelvic Pain (%) Responder (0-3 VRS) Dysmenorrhea (%) Non-menstrual Pelvic Pain (%) Responder (0-3 VRS) Responder (0-3 VRS) ** * *** *** * * p value <0.05 ** p value <0.01 *** p value <0.001 for linzagolix doses compared to placebo

Phase 2b EDELWEISS trial 75mg effective without significantly affecting BMD Lumbar Spine Total hip Femoral neck 200mg 100mg 75mg FD 50mg Placebo Mean % change in BMD from baseline to 24 weeks (12 weeks for placebo) * ABT: Add Back Therapy (estradiol + norethindrone acetate) 75mg 200mg Error bars are 95% CIs -1.6% lower bound Cl for 75mg -3.6% lower bound Cl for 200mg

Linzagolix Phase 3 Endometriosis trials: EDELWEISS 2 and 3 MAIN STUDY FOLLOW UP 11±5 WEEKS 6 MONTHS TREATMENT 6 MONTHS EXTENSION STUDY 6 MONTHS CO-PRIMARY ENDPOINT: DYS/ NMPP RESPONDER ANALYSIS LEAD-IN INITIATED 1H:19 200mg daily + ABT 75mg daily PLACEBO 75mg daily 200mg daily + ABT 75mg daily 200mg daily + ABT FOLLOW-UP

Differentiated regimen offering compelling commercial proposition Linzagolix: a significant opportunity LINZAGOLIX is the only GnRH antagonist intended to be developed as two different, SIMPLE & WELL TOLERATED regimens for both indications Significant revenue opportunity Potentially best-in-class GnRH antagonist Large markets with significant unmet need in U.S. ~ 4M treated for heavy menstrual bleeding resulting from uterine fibroids ~ 5M treated for endometriosis associated pain Best-in-class response for HMB control in uterine fibroids and pain control in endometriosis with full suppression option Only option under development for women with uterine fibroids who cannot or do not want to take ABT in both indications Convenient, oral, once-daily dosing 1 2 3 IP protection beyond 2036

OBE022 Potential to delay preterm birth to improve newborn health and reduce medical costs

Preterm DELIVERY: Life altering & costly Preterm labor is the Tremendous avoidable medical & societal cost 1in10 babies are born premature premature deaths in 2015 of death of children under 5 years of age LEADING CAUSE more than 1million Average cost for a preterm infant (U.S.) $50K Average cost per survivor infant born 24-26 weeks $195K Babies surviving early birth face greater likelihood of lifelong disabilities U.S. economic burden $26B+ $16.9B+ U.S. Infant medical care costs

Mode of action of Pgf2a receptor antagonist to control preterm labor PGE2 PGF2a PGHS - 1/2 = COX1/2 EP1 EP3 EP2 EP4 FP PGH2 contract relax contract Selectively blocks the PGF2a receptor Has the potential to treat preterm labor with improved safety over NSAIDs OBE022 UTERUS: Phospholipids Arachidonic Acid x

OBE022: PROLONG Ph2a Study Part B Study design: Double-blind, randomized Atosiban + OBE022 versus Atosiban + Placebo 24-month Infant FU Q1:18 Final Part B: Main analysis 2H:20 2H:22 Endpoint: Complete 7 days of dosing without delivery Main Study completion 120 patients Dosing: 7 days up to 60 patients Followed thru delivery Interim Update 60 patients Interim Update 30 patients IDMC Reviews

financial outlook 2020 investment includes FOUR ONGOING Phase 3 trials: SEPTEMBER 30, 2019 CASH: $91 million EXPECTED CASH RUNWAY: Q1:21 with credit facility PRIMROSE 1 PRIMROSE 2 EDELWEISS 2 EDELWEISS 3